© Rosalind Scientific LLC 2018-2022
© Rosalind Scientific LLC, 2018-2022
New Drug Hunter content, featured events and job postings straight to your inbox. Trusted by >3,500 drug hunters worldwide, unsubscribe anytime.
<< Back to November
dual orexin receptor GPCR antagonist
Ph. III efficacy for insomnia, oral 25-50 mg
from optimization of prior clinical candidate
ChemMedChem., Oct. 28, 2020
Idorsia Pharmaceuticals, Allschwil, CH
Idorsia clinical dual orexin receptor GPCR antagonist
Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.